8-K: Tarsus Pharmaceuticals Reports Strong Q4 and Full-Year 2024 Results Driven by XDEMVY Sales

Tarsus Pharmaceuticals announces robust financial results for Q4 and full-year 2024, fueled by strong sales of XDEMVY and advancements in its pipeline.

Summary

• Tarsus Pharmaceuticals reported its Q4 and full-year 2024 financial results on February 25, 2025.
• The company generated $66.4 million in net product sales of XDEMVY in Q4 2024 and $180.1 million for the full year.
• Approximately 58,500 bottles of XDEMVY were dispensed to patients in Q4 2024, and over 163,000 bottles for the full year.
• Gross-to-net discount for XDEMVY was approximately 45% in both Q4 and full-year 2024.
• The company's net loss for Q4 2024 was $23.1 million, compared to $41.9 million in the same period in 2023.
• The net loss for the full year 2024 was $115.6 million, compared to $135.9 million in 2023.
• As of December 31, 2024, Tarsus had $291.4 million in cash, cash equivalents, and marketable securities.
• Tarsus is advancing TP-04 for Ocular Rosacea, with plans to initiate a Phase 2 study in the second half of 2025.
• The company is also progressing TP-05 for the potential prevention of Lyme disease, with a planned Phase 2 study in hundreds of patients and a Phase 3 prevention study in thousands of patients.
• Tarsus expects potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong sales growth of XDEMVY and advancements in the pipeline. However, the company is still operating at a loss, and there are risks associated with commercialization and regulatory approvals.

Positives

• XDEMVY has demonstrated strong sales growth, generating $180.1 million in its first full year of launch.
• The company has secured broad reimbursement coverage for XDEMVY, reaching over 90% of covered lives.
• Tarsus is advancing its pipeline with TP-04 for Ocular Rosacea and TP-05 for Lyme disease prevention.
• The company has a clear regulatory path forward for TP-04 based on positive FDA feedback.
• Tarsus has a strong cash position of $291.4 million as of December 31, 2024.
• The company's net loss decreased from $135.9 million in 2023 to $115.6 million in 2024.

Negatives

• The company experienced a net loss of $115.6 million for the full year 2024.
• Selling, general, and administrative (SG&A) expenses increased significantly to $237.3 million in 2024, primarily due to commercial and marketing costs related to the XDEMVY launch.
• The gross-to-net discount for XDEMVY was approximately 45% in both Q4 and full-year 2024.

Risks

• Tarsus is heavily dependent on the successful commercialization of XDEMVY.
• The company's future success depends on obtaining and maintaining regulatory approval for its products.
• Tarsus has incurred significant losses and negative cash flows since inception and anticipates continuing to do so.
• The company may need to obtain additional funding to achieve its goals.
• The market opportunity for XDEMVY and Tarsus' product candidates may be smaller than estimated.
• The results of Tarsus' earlier studies and trials may not be predictive of future results.
• Tarsus' development and commercialization of products is dependent on intellectual property it licenses from Elanco Tiergesundheit AG.

Future Outlook

Tarsus anticipates continued growth of XDEMVY, advancement of its pipeline programs (TP-04 and TP-05), potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027, and further expansion into international markets like Japan and China.

Management Comments

• Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus, stated that Tarsus' demonstrated category-creating blueprint has established XDEMVY as one of the most successful eye care launches to date.
• Dr. Azamian believes that Tarsus is only beginning to unlock its full potential as the next leader in eye care.

Industry Context

Tarsus is operating in the eye care market, focusing on underserved conditions like Demodex blepharitis and Ocular Rosacea. The company's success with XDEMVY positions it as a potential leader in this space, competing with established players and other emerging companies developing novel treatments for eye diseases.

Comparison to Industry Standards

• XDEMVY's launch is being compared to other successful eye care product launches, suggesting a high level of market acceptance.
• The company's focus on Ocular Rosacea, a condition with no FDA-approved therapies, positions it to potentially capture a significant market share, similar to how companies like Alcon and Bausch + Lomb have dominated specific segments of the eye care market.
• Tarsus' approach to Lyme disease prevention with TP-05 is unique, as it targets the tick vector rather than the disease itself, differentiating it from vaccine-based approaches.

Management Changes

Stakeholder Impact

• Shareholders: The strong financial results and pipeline advancements are likely to positively impact shareholder value.
• Employees: The company's growth and expansion may create new job opportunities and career advancement prospects.
• Patients: The development and commercialization of new treatments like XDEMVY, TP-04, and TP-05 could improve patient outcomes and quality of life.
• Customers: Eye Care Professionals (ECPs) will have access to new and innovative treatment options for their patients.
• Suppliers: Increased demand for XDEMVY and other products may lead to higher sales volumes for suppliers.

Next Steps

• Initiate a Phase 2 study for TP-04 in the second half of 2025.
• Advance TP-05 for Lyme disease prevention through Phase 2 and Phase 3 studies.
• Share results from a DB prevalence study in Japan in the first half of 2025.
• Meet with Japanese regulatory authorities to determine a regulatory path forward.
• Continue DTC campaign on streaming platforms and expand into network television.
• Pursue potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027.

Key Dates

Keywords

XDEMVY, Tarsus Pharmaceuticals, Ocular Rosacea, Lyme disease, TP-04, TP-05, Financial Results, Demodex blepharitis, Eye care